Title Image


About Us

Dy­nam­ic42 was founded in the spring of 2018 in the high-tech city of Jena and is cur­rently lo­cated at the BioIn­stru­mentezen­trum on the Beuten­berg. The still young com­pany is a spin-off of the Uni­ver­sity Hos­pi­tal Je­na. We de­velop and mar­ket nov­el, three-di­men­sion­al, hu­man or­gan mod­els (so-called or­gan-on-chip tech­nol­o­gy) for pre­clin­i­cal re­search and de­vel­op­ment as well as for test­ing novel phar­ma­ceu­ti­cal prod­ucts, chem­i­cals and food ad­di­tives.


We are spe­cial­ized in the area of or­gan-on-chip tech­nol­ogy in the in­te­gra­tion of the im­mune sys­tem, which plays a sig­nif­i­cant role in the oc­curence of ad­verse ef­fects of drugs and has been ne­glected in the in­dus­try and in two-di­men­sional test sys­tems. Our plat­form en­ables tox­i­c­ity screen­ings and AD­MET stud­ies al­ready in pre­clin­i­cal phases on com­plex mi­cro­phys­i­o­log­i­cal mod­els of hu­man or­gans. Hereby we ac­com­pany com­mer­cial man­u­fac­tur­ers as well as sci­en­tists in the field of re­search and de­vel­op­ment in the de­sign and ex­e­cu­tion of pre­clin­i­cal stud­ies.


In ad­di­tion, we de­velop hu­man dis­ease mod­els in our chip plat­form both in­ter­nally and with ex­ter­nal part­ners – es­pe­cially in ar­eas where no an­i­mal mod­els are avail­able.


With the pro­vi­sion of hu­man mi­cro­phys­i­o­log­i­cal sys­tems / or­gan-on-chip tech­nol­o­gy, Dy­nam­ic42 GmbH ad­dresses crit­i­cal points in the de­vel­op­ment of ap­pli­ca­tions for many ar­eas where chem­i­cal sub­stances and bi­o­log­i­cal com­pounds come into di­rect contact with hu­mans or are used in prod­ucts for hu­mans. Here, we con­tribute to in­crease the va­lid­ity of data ob­tained dur­ing pre-clin­i­cal trial phases by test­ing on hu­man mi­cro­phys­i­o­log­i­cal or­gan mod­els. Thus, re­sults are bet­ter trans­fer­able into the hu­man sit­u­a­tion in clin­i­cal trial phas­es.


To achieve this, we of­fer a ma­jor ad­van­tage with many years of ex­per­tise in han­dling and in­te­grat­ing im­mune cells into our hu­man mi­cro­phys­i­o­log­i­cal mod­els as tis­sue-res­i­dent com­po­nents or via the cir­cu­la­tion within the cell cul­ture me­dia.


On the one hand, test­ing in our hu­man mi­cro­phys­i­o­log­i­cal mod­els will im­prove the de­vel­op­ment of com­pounds with less side ef­fects for hu­mans. On the other hand, chances of costly ad­just­ments or even ter­mi­na­tion of stud­ies in late-stage clin­i­cal trial phases will be re­duced.


Con­comi­tant, we strive to re­duce an­i­mal ex­per­i­men­ta­tion by us­ing our mi­cro­phys­i­o­log­i­cal sys­tems. Due to their cel­lu­lar com­plex­i­ty, they of­fer in­creased data va­lid­ity com­pared to stan­dard cell cul­ture of in­di­vid­ual cell types. Sub­se­quent­ly, an­i­mal ex­per­i­men­ta­tion can thus be kept at a min­i­mal lev­el. Fur­ther, if the de­vel­op­ment of a stan­dard al­ter­na­tive test method is con­sid­ered for in­di­vid­ual ap­pli­ca­tions, we would like to con­tribute to es­tab­lish and pro­vide so­lu­tions in those cas­es.


Our com­pany would like to con­tribute to the eco­nom­i­cal and sus­tain­able de­vel­op­ment of phar­ma­ceu­ti­cals and ad­di­tives. We want to dis­trib­ute mod­ern, hu­man cell cul­ture-based so­lu­tions with in­te­grated lat­est tech­nolo­gies in or­der to min­i­mize or re­place an­i­mal ex­per­i­men­ta­tion. Thus, our prin­ci­ple is to pro­mote eth­i­cal val­ues and sus­tain­abil­ity in re­search and de­vel­op­ment.


Sec­ond­ly, the well-be­ing of hu­mans rep­re­sents an im­por­tant value to our com­pa­nies iden­ti­ty. The im­prove­ment of de­vel­op­men­tal pro­ce­dures and test meth­ods by us­ing com­plex hu­man mi­cro­phys­i­o­log­i­cal or­gan mod­els en­ables an in­crease in safety of newly de­vel­oped drugs and ad­di­tives and de­creases their chance in bear­ing se­vere side ef­fects. Our daily mo­ti­va­tion is to de­velop new ap­pli­ca­tions as well as to im­prove and tech­no­log­i­cally ex­pand our plat­form to achieve these goals.

We are hiring!

We are looking for you! Whether as a researcher or administrative employee – there is still room for you in our team. Take a look at our vacancies now. Didn’t find a suitable position? Then simply apply on your own initiative!


Latest Company News


We are delighted to announce that Dr. Juliane Fischer has joined our team and will from now on heading all Marketing efforts at Dynamic42.

Read More

Following their Master's studies, Daria and Sophie join our lab team as research assistants.

Read More

The RUBIN Alliance "ATHANA" (antifungal therapy approaches with nanoparticle-based targeting of drugs) is developing innovative therapeutic approaches for the treatment of infectious diseases, in particular fungal infections.

Read More

Do not miss any news!


Sign up now for our Dynamic42 newsletter and don’t miss anything else from the orang-on-a-chip industry!

Get to know our Team!


Find out now who is behind Dynamic42.

Our Team